- Home
- SDHC vs NRIX Comparison
SDHC vs NRIX Comparison
Compare SDHC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- NRIX
- Stock Information
- Founded
- SDHC 2008
- NRIX 2009
- Country
- SDHC United States
- NRIX United States
- Employees
- SDHC N/A
- NRIX N/A
- Industry
- SDHC
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- SDHC
- NRIX Health Care
- Exchange
- SDHC Nasdaq
- NRIX Nasdaq
- Market Cap
- SDHC 933.4M
- NRIX 970.1M
- IPO Year
- SDHC 2024
- NRIX 2020
- Fundamental
- Price
- SDHC $19.51
- NRIX $11.21
- Analyst Decision
- SDHC Hold
- NRIX Strong Buy
- Analyst Count
- SDHC 4
- NRIX 15
- Target Price
- SDHC $23.63
- NRIX $29.13
- AVG Volume (30 Days)
- SDHC 66.1K
- NRIX 993.2K
- Earning Date
- SDHC 08-06-2025
- NRIX 07-09-2025
- Dividend Yield
- SDHC N/A
- NRIX N/A
- EPS Growth
- SDHC N/A
- NRIX N/A
- EPS
- SDHC 0.24
- NRIX N/A
- Revenue
- SDHC $1,010,976,000.00
- NRIX $88,381,000.00
- Revenue This Year
- SDHC $3.34
- NRIX $71.51
- Revenue Next Year
- SDHC $9.42
- NRIX N/A
- P/E Ratio
- SDHC $82.98
- NRIX N/A
- Revenue Growth
- SDHC 28.67
- NRIX 41.86
- 52 Week Low
- SDHC $16.28
- NRIX $8.18
- 52 Week High
- SDHC $39.50
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- SDHC 50.95
- NRIX 44.64
- Support Level
- SDHC $18.55
- NRIX $11.13
- Resistance Level
- SDHC $23.50
- NRIX $12.33
- Average True Range (ATR)
- SDHC 1.05
- NRIX 0.53
- MACD
- SDHC -0.14
- NRIX -0.08
- Stochastic Oscillator
- SDHC 30.49
- NRIX 26.47
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.